HORMONE RECEPTOR POSITIVE TUMOR
Clinical trials for HORMONE RECEPTOR POSITIVE TUMOR explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE TUMOR trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat breast cancer: targeted combo enters late-stage trial
Disease control Recruiting nowThis study compares two drug combinations for people with a type of advanced breast cancer (HR+/HER2-) that has a specific genetic change (PIK3CA mutation) and has worsened after prior treatment. About 540 adults will receive either the experimental drug RLY-2608 plus fulvestrant…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE3 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill targets Hard-to-Treat cancers with PIK3CA mutation
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE1 • Sponsor: Regor Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New precision approach aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis Phase 2 trial at Fudan University tests several targeted drug combinations given before surgery for early-stage breast cancer. The goal is to see which combinations best eliminate all signs of cancer (pathological complete response) based on each tumor's specific subtype. Ab…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could a 4-Week drug combo shrink breast tumors before surgery?
Disease control Recruiting nowThis phase 2 trial is testing whether the drug elacestrant, given alone or with triptorelin (which temporarily stops ovary hormone production), can slow or shrink hormone-sensitive breast tumors in premenopausal women. About 96 women will take the pills daily for 30 days before t…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could electromagnetic waves help shrink breast tumors before surgery?
Disease control Recruiting nowThis pilot study is testing whether a device called TheraBionic P1, which delivers targeted electromagnetic fields, can affect breast cancer tumors before surgery. About 24 women with early-stage, hormone receptor-positive, HER2-negative breast cancer will use the device three ti…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: NA • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill INX-315 takes on advanced breast and ovarian cancers
Disease control Recruiting nowThis study tests a new oral drug called INX-315 in 150 people with advanced breast cancer, ovarian cancer, or other solid tumors that have not responded to standard treatments. The drug is given alone or combined with other cancer drugs (fulvestrant or abemaciclib). The goal is t…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Incyclix Bio • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Breast cancer trial aims to match drugs to tumors for personalized care
Knowledge-focused Recruiting nowThis study is testing new drug combinations for breast cancer to see which ones work best for different tumor types. It involves up to 5,000 people with early-stage or locally advanced breast cancer. Researchers use MRI scans and tissue samples before surgery to predict treatment…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Phase: PHASE2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Do breast cancer patients stick to their meds? new study aims to find out
Knowledge-focused Recruiting nowThis study will follow 319 women with early-stage, hormone-sensitive, HER2-negative breast cancer to see how well they take their prescribed aromatase inhibitors, with or without the added drug abemaciclib. Researchers will measure adherence using pill counts and questionnaires a…
Matched conditions: HORMONE RECEPTOR POSITIVE TUMOR
Sponsor: Institute of Oncology Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC